MOYES JAY M 4

What Happened

• Jay M. Moyes, a director of PUMA BIOTECHNOLOGY, received a grant of 27,000 restricted stock units (RSUs) on 2026-06-11 (acquired at $0.00) and sold 22,000 shares in an open-market transaction on 2026-06-12.
• The sale was for a weighted average price of $7.22 per share, totaling $158,796. The RSU grant will vest in full on the earlier of one year from the grant date or the next annual shareholder meeting, subject to continued service.

Key Details

• Transaction dates: RSU grant 2026-06-11; open-market sale 2026-06-12.
• Sale price: weighted average $7.22; reported range of sale prices $6.98–$7.32 (sales occurred in multiple trades). The filer offers to provide a breakdown on request (footnote F3).
• RSU vesting terms: full vesting on the earlier of one-year anniversary or next annual meeting, subject to continued service (footnote F1).
• 10b5-1 plan: sale was covered by a pre-established 10b5-1(c) plan adopted 2025-03-12 (footnote F2).
• Shares owned after the transactions: not specified in the provided filing excerpt.
• Filing timeliness: Form 4 was filed on 2026-06-15 for transactions on 6/11–6/12, which appears to meet the two-business-day reporting requirement.

Context

• The RSU grant is an award (no cash outlay) that vests over time and does not by itself indicate buying or selling sentiment.
• The sale was executed under a 10b5‑1 plan (pre-arranged trading plan), a common mechanism insiders use to sell shares without timing decisions tied to material nonpublic information.